Le Lézard
Classified in: Health
Subjects: NPT, CHI, SVY, LGB, DEI

Do No Harm Launches Nationwide Campaign to Protect Minors from Gender Ideology


RICHMOND, Va., Jan. 26, 2023 /PRNewswire/ -- Do No Harm has announced its latest initiative "Protecting Minors from Gender Ideology," an effort to educate policymakers and the public on the disastrous consequences of the unproven and often harmful practice known as "gender-affirming care."

"Gender-affirming care" is based on the premise that children and adolescents know best whether their feelings of discomfort with their bodies should be grounds for "treatment" with risky and experimental drugs and surgeries.

Do No Harm is committed to ensuring children who are diagnosed with, or believe they have, "gender dysphoria" are treated with the utmost care, caution, and concern.

"The movement to promote 'gender affirming care' is profoundly dangerous and driven by ideology rather than evidence," said Dr. Stanley Goldfarb, MD, chairman of Do No Harm. "At their core, medical professionals who support these efforts are violating the Hippocratic oath directive to 'do no harm' by ignoring key consequences of this type of 'care,' including the fact that underlying mental health concerns are usually not addressed."

Dr. Goldfarb notes that so-called "gender-affirming care" ignores the impossibility of informed consent for the child: "The procedures themselves can lead to physical impairment, including a lack of bone strength and brain maturation, and the loss of fertility. 'Gender transitioning' prior to maturation can lead to sexual dysfunction, including atrophy and necrosis of genital tissue, chronic pain, incontinence, and the inability to orgasm."

As part of this launch, Do No Harm is releasing a new white paper, drafted with the help of Cooper & Kirk, PLLC explaining the harms of these life-changing medical procedures and a comprehensive report identifying the different legal requirements for sex change-related treatments and actions between the US and western European countries.

In addition, Do No Harm is providing model legislation, "The JUST FACTs Act" (The JUSTice for Adolescent and Child Transitioners Act) to legislators in multiple states who want help navigating this challenging issue. The model legislation:

Finally, Do No Harm has engaged a number of well-respected senior fellows, including physicians, parents, patients, and detransitioner Chloe Cole, to share their medical expertise and personal experiences dealing with gender ideology through testimony and public presentations.

About Do No Harm

Do No Harm is a diverse group of physicians, healthcare professionals, medical students, patients, and policymakers united by an ethical mission: Protect healthcare from a radical, divisive, and discriminatory ideology. They believe in making healthcare better for all ? not undermining it in pursuit of a political agenda. Learn more at www.donoharmmedicine.org 

SOURCE Do No Harm


These press releases may also interest you

at 05:12
"According to the latest BCC Research study, the demand for Global Skin Allergy Testing Market is expected to grow from $560 million in 2023 and is projected to reach $771.5 million...

at 03:30
Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the publication of a...

at 03:30
Commit Biologics ("Commit"), a pioneer in the...

at 03:29
Hugel, a global total medical aesthetics company, announced its 1Q24 consolidated financial results on the 9th, reporting revenue of KRW 74.3 billion, operating profit of KRW 24 billion, and net income of KRW...

at 03:00
"LASTE" (LArge Stroke Therapy Evaluation), a prospective, randomized, controlled trial co-led by Professor Vincent Costalat (neuroradiologist, Montpellier, France) and Dr. Caroline Arquizan (vascular neurologist,...

at 03:00
Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into an exclusive licensing agreement with Tabuk Pharmaceuticals Manufacturing Company ("Tabuk"), for exclusive rights to the commercialization of...



News published on and distributed by: